Daliresp and Veramyst drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Daliresp (roflumilast) and Veramyst (fluticasone furoate). Common drug interactions include dyspnoea among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people have when they take Daliresp and Veramyst. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Daliresp?

Daliresp has active ingredients of roflumilast. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 4,722 Daliresp users. Check the latest studies of Daliresp.

What is Veramyst?

Veramyst has active ingredients of fluticasone furoate. It is often used in allergies. eHealthMe is studying from 3,444 Veramyst users. Check the latest studies of Veramyst.

On Jul, 30, 2026

20 people who take Daliresp and Veramyst together, and have interactions are studied.

Daliresp and Veramyst drug interactions.

What are the common drug interactions of Daliresp and Veramyst, by gender? *:

female:

Dyspnoea (difficult or laboured respiration)
Asthenia (weakness)
Acute respiratory failure
Cough
Dysstasia (difficulty in standing)
Fatigue (feeling of tiredness)
Hypoxia (low oxygen in tissues)
Pneumonia bacterial (pneumonia associated with bacterial infection)
Productive cough
Respiratory tract congestion (blockage on respiratory system)

male:

Dyspnoea (difficult or laboured respiration)
Renal failure (kidney dysfunction)
Back pain
Cough
Disability
Drug administration error
Dyspepsia (indigestion)
Dysphonia (speech disorder attributable to a disorder of phonation)
Dyspnoea exertional (breathlessness or shortness of breath)
Fatigue (feeling of tiredness)

What are the common drug interactions of Daliresp and Veramyst, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Chronic kidney disease
Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
Nephrogenic anaemia (anaemia due to kidney disease)
Renal failure (kidney dysfunction)
Fatigue (feeling of tiredness)
Renal injury (kidney injury)
Back pain
Cough
Disability
Drug administration error

60+:

Dyspnoea (difficult or laboured respiration)
Abdominal distension
Pneumonia bacterial (pneumonia associated with bacterial infection)
Productive cough
Respiratory tract congestion (blockage on respiratory system)
Decreased appetite
Diarrhoea
Dyspepsia (indigestion)
Lung hyperinflation (inspiration of more than normal)
Nausea (feeling of having an urge to vomit)

What are the existing conditions these people have? *

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 25.00%
High Blood Pressure: 4 people, 20.00%
Hypersensitivity: 3 people, 15.00%
Stress And Anxiety: 3 people, 15.00%
Stable Angina (a constant chest pain): 3 people, 15.00%
Blood Calcium Decreased: 3 people, 15.00%
Constipation: 3 people, 15.00%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 3 people, 15.00%
Dizziness: 3 people, 15.00%
Pain: 3 people, 15.00%

* Approximation only. Some reports may have incomplete information.

Do you take Daliresp and Veramyst?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously